Serge Beaulieu

Serge Beaulieu

Auto-generated profile, based on publicly available information

Serge Beaulieu

Department of Psychiatry, McGill University

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2018 in Bipolar Disorders
Verified
Journal Article
Open access
PDF file
LYLakshmi N Yatham
Lakshmi N Yatham
SKSidney H Kennedy
Sidney H Kennedy
SPSagar V Parikh
Sagar V Parikh
ASAyal Schaffer
Ayal Schaffer
DBDavid J Bond
David J Bond
MBMichael Berk
Michael Berk
The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar Disorders (ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments. These advances have been translated into clear and easy to use recommendations for first, second, and third‐ line treatments, with consideration given to levels of evidence for efficacy, clinical support based on experience, and consensus ratings of safety, tolerability, and treatment‐emergent switch risk. New to these guidelines, hierarchical rankings were created for first and second‐ line treatments recommended for acute mania, acute depression, and maintenance treatment in bipolar I disorder. Created by considering the impact of each treatment across all phases of illness, this hierarchy will further assist clinicians in making evidence‐based treatment decisions. Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine alone or in combination are recommended as first‐line treatments for acute mania. First‐line options for bipolar I depression include quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or adjunctive lamotrigine. While medications that have been shown to be effective for the acute phase should generally be continued for the maintenance phase in bipolar I disorder, there are some exceptions (such as with antidepressants); and available data suggest that lithium, quetiapine, divalproex, lamotrigine, asenapine, and aripiprazole monotherapy or combination treatments should be considered first‐line for those initiating or switching treatment during the maintenance phase. In addition to addressing issues in bipolar I disorder, these guidelines also provide an overview of, and recommendations for, clinical management of bipolar II disorder, as well as advice on specific populations, such as women at various stages of the reproductive cycle, children and adolescents, and older adults. There are also discussions on the impact of specific psychiatric and medical comorbidities such as substance use, anxiety, and metabolic disorders. Finally, an overview of issues related to safety and monitoring is provided. The CANMAT and ISBD groups hope that these guidelines become a valuable tool for practitioners across the globe.


14 April 2009 in Bipolar Disorders
Verified
Journal Article
Closed access
PDF file
LYLakshmi N Yatham
Lakshmi N Yatham
SKSidney H Kennedy
Sidney H Kennedy
ASAyal Schaffer
Ayal Schaffer
SPSagar V Parikh
Sagar V Parikh
SBSerge Beaulieu
Serge Beaulieu
FKFlávio Kapczinski
Flávio Kapczinski

6 May 2024 in The Canadian Journal of Psychiatry
Verified
Journal Article
Open access
RLRaymond W. Lam
Raymond W. Lam
SKSidney H. Kennedy
Sidney H. Kennedy
GAG. Camelia Adams
G. Camelia Adams
ABAnees Bahji
Anees Bahji
SBSerge Beaulieu
Serge Beaulieu
RMRoumen Milev
Roumen Milev
Background: The Canadian Network for Mood and Anxiety Treatments (CANMAT) last published clinical guidelines for the management of major depressive disorder (MDD) in 2016. Owing to advances in the field, an update was needed to incorporate new evidence and provide new and revised recommendations for the assessment and management of MDD in adults. Methods: CANMAT convened a guidelines editorial group comprised of academic clinicians and patient partners. A systematic literature review was conducted, focusing on systematic reviews and meta-analyses published since the 2016 guidelines. Recommendations were organized by lines of treatment, which were informed by CANMAT-defined levels of evidence and supplemented by clinical support (consisting of expert consensus on safety, tolerability, and feasibility). Drafts were revised based on review by patient partners, expert peer review, and a defined expert consensus process. Results: The updated guidelines comprise eight primary topics, in a question-and-answer format, that map a patient care journey from assessment to selection of evidence-based treatments, prevention of recurrence, and strategies for inadequate response. The guidelines adopt a personalized care approach that emphasizes shared decision-making that reflects the values, preferences, and treatment history of the patient with MDD. Tables provide new and updated recommendations for psychological, pharmacological, lifestyle, complementary and alternative medicine, digital health, and neuromodulation treatments. Caveats and limitations of the evidence are highlighted. Conclusions: The CANMAT 2023 updated guidelines provide evidence-informed recommendations for the management of MDD, in a clinician-friendly format. These updated guidelines emphasize a collaborative, personalized, and systematic management approach that will help optimize outcomes for adults with MDD.

6 June 2005 in Bipolar Disorders
Verified
Journal Article
Closed access
PDF file
LYLakshmi N Yatham
Lakshmi N Yatham
SKSidney H Kennedy
Sidney H Kennedy
COClaire O'Donovan
Claire O'Donovan
SPSagar Parikh
Sagar Parikh
GMGlenda MacQueen
Glenda MacQueen
CGChris P Gorman
Chris P Gorman

27 November 2006 in Bipolar Disorders
Verified
Journal Article
Closed access
PDF file
LYLakshmi N Yatham
Lakshmi N Yatham
SKSidney H Kennedy
Sidney H Kennedy
COClaire O'DOnovan
Claire O'DOnovan
SPSagar V Parikh
Sagar V Parikh
GMGlenda MacQueen
Glenda MacQueen
FGfor CANMAT guidelines group
for CANMAT guidelines group